SCHEMBL19035674

SCHEMBL19035674

CN1CCCN(c2cnccn2)CC1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.50
LMNA P02545 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SORD Q00796 1/20 0.47
ROCK2 O75116 4/20 0.46
ROCK1 Q13464 3/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
HRH3 Q9Y5N1 3/20 0.44
HTR1A P08908 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2074813 0.93 LMNA (0.54) HRH4LMNAL3MBTL1SORDKDM4E
SCHEMBL2320496 0.83 SORD (0.51) LMNAL3MBTL1SORDKDM4EALDH1A1
SCHEMBL18228513 0.83 SORD (0.51) LMNAL3MBTL1SORDKDM4EALDH1A1
SCHEMBL31014265 0.83 SORD (0.51) LMNAL3MBTL1SORDKDM4EALDH1A1
SCHEMBL468382 0.81 SORD (0.50) HRH4LMNAL3MBTL1SORDKDM4E
SCHEMBL2320514 0.81 SORD (0.50) HRH4LMNAL3MBTL1SORDKDM4E
SCHEMBL30785422 0.81 SORD (0.50) HRH4LMNAL3MBTL1SORDKDM4E
SCHEMBL26194492 0.79 LMNA (0.46) LMNAL3MBTL1SORDKDM4EALDH1A1
SCHEMBL17198008 0.79 LMNA (0.46) LMNAL3MBTL1SORDKDM4EALDH1A1
SCHEMBL19035675 0.79 HRH3 (0.47) LMNAL3MBTL1SORDKDM4EHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10301267-B2 Compounds ASTRAZENECA AB (SE) 2019-05-28 US disclosed
US-20170260143-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2017-09-14 US disclosed
US-9688640-B2 Methods of treating cancer with a pyrazole derivative ASTRAZENECA AB (SE) 2017-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10301267-B2 Compounds SLC10A1, CYP11B1, ABCB11 HRH4 3347/4885LMNA 2866/4885L3MBTL1 4338/4885
US-20170260143-A1 NOVEL COMPOUNDS SLC10A1, ABCB11, CYP11B1 HRH4 3520/4885LMNA 3279/4885L3MBTL1 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.